Overall verdict
Sell
1.5/10
1-year performance
-10.21%
Score breakdown
Down 10.2% over 1 year, 3% of the 52-week range.
Strongest: Financial strength 5.8/10. Weakest: Growth 0.0/10.
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers.
It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
Ireland
CEO
Aaron Berg
Founded
1989
Employees
80
Revenue / employee
2.7M USD
Next earnings
October 28, 2026 (estimated)
Institutional holders
- Sarissa Capital Management LP7.61%
- ACADIAN ASSET MANAGEMENT LLC3.28%
- Kynam Capital Management, LP2.42%
- MORGAN STANLEY1.02%
- Waterfront Wealth Inc.0.97%
- Brooklands Fund Management Ltd0.81%
- Eversept Partners, LP0.66%
- MILLENNIUM MANAGEMENT LLC0.53%
- TWO SIGMA INVESTMENTS, LP0.46%
- Other institutions3.43%
- Rest of the register78.81%
83 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
20.90 USD
52-week low
12.96 USD
1-year performance
-10.21%
Declining
Year-to-date performance
-2.14%
Declining
Drawdown
-36.94%
Major drawdown
Position in the 52-week range
3% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did clearly worse than the world ETF once risk is accounted for. It earned less, while shaking 10.3 times harder.
10,000 € placed at the end of September 2009 are worth today
| Amarin | 5 778 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 10.3 times as much as the world ETF.
- Worst fall:-98 % between November 2019 and April 2025. 10,000 € placed at the top fell to 168 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Amarin earned less than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Amarin: 5 778 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Gross margin 40.4%, the company loses 14.6% of its revenue, ROIC -5.9%, ROE -6.0%.
Net margin
-14.57%
Negative
Sector -229.34%|S&P 12.97%
Gross margin
40.42%
High
Return on equity (ROE)
-5.96%
Negative
Sector -58.37%|S&P 16.52%
Return on invested capital (ROIC)
-5.88%
Negative
Free cash flow margin (FCF)
8.37%
Fair
Margin stability
20.7 pts
Very uneven
Revenue to net income
Growth
0.0/10Revenue down 42.6% over 1 year, -19.1% a year over 5.
Revenue (trailing 12 months)
186M USD
Revenue growth (1y)
-42.58%
Declining
Revenue growth (3y)
-41.96%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
1.1/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.3x|S&P 23.0x
Forward P/E (adjusted)
—
EV / EBITDA
—
N/A (loss)
Sector 13.4x|S&P 14.5x
PEG
—
Sector 1.05|S&P 0.86
P/E vs its own 5-year history
among the 31% lowest valuations
Cheaper than usual
Market cap
290M USD
Financial strength
5.8/10Cash covers 5991.4% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-69.79%
Net cash
Cash
315M USD
Cash / market cap
108.64%
Very solid
Cash / total debt
5991.44%
Net cash
Interest coverage
-7167.1x
Stretched
Net debt
-310M USD
Equity
444M USD
Closed daily candles, 2 years
Last close on September 24, 2026: 13.43 USD
- MM2013.85
- MM5013.98
- MM20014.59
- RSI 1439.9
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-1.61%
200-day average slope, 3 months
-5.29%
50-day average slope, 1 month
-4.91%
Bullish RSI divergence
No
20-day volatility
1.60 % per day
Volatility change
-13.17%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.07 (1) | -0.02 (1) | 177 (2) | -39 (2) | -27 (2) |
| 2027 | -0.06 (1) | 0.98 (1) | 177 (2) | -30 (2) | -18 (2) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of August 21, 2026.
Same sub-industry: 734 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RCKT | 6.8 | N/A | 332M USD | Not meaningful (loss) | — | — | -4.5 % | 1.4x | -51.4 % | -14.6 % | ||
| 2 | CUV | 6.5 | 6.3 | 294M USD | 12.4x | 36.1 % | -1.0 % | 13.2 % | -6.0x | 8.3 % | -29.0 % | ||
| 3 | XFOR | 4.9 | 2.5 | 308M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -13.3 % | ||
| 4 | IKT | 4.4 | 0.9 | 300M USD | Not meaningful (loss) | — | — | -52.0 % | 2.4x | -14.2 % | 29.6 % | ||
| 5 | CATX | 4.4 | 1.6 | 299M USD | Not meaningful (loss) | -28516.1 % | -72.1 % | -39.2 % | 2.1x | -40.6 % | -21.4 % | ||
| 6 | SANN | 4.0 | 3.5 | 286M USD | Not meaningful (loss) | -63.8 % | 97.3 % | -62.8 % | -2.3x | -15.4 % | 25.2 % | ||
| 7 | ALERS | 3.6 | 4.1 | 287M USD | 51.9x | 2.9 % | 9.1 % | 2.6 % | -0.1x | 1.9 % | -1.4 % | ||
| 8 | A174900 | 2.1 | 2.2 | 285M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 0.2x | -3.1 % | 27.3 % | ||
| 9 | AMRN | 1.5 | 1.5 | 290M USD | Not meaningful (loss) | -14.6 % | -42.6 % | -5.9 % | — | 5.4 % | -10.2 % |
